Medincell's Stock Bounces Nearly 2% and Ranks Among the Top of the SBF 120
The biotech company from Montpellier moves forward at midday, in stark contrast to a declining Parisian market. The stock climbs to the forefront of the SBF 120, even as technical indicators remain weak following a drop after the annual financial report was released.
A Rise Contrary to a Sharply Declining CAC 40
Medincell gains 1.83% to €24.52 during the session, while the CAC 40 loses 0.72% at 8,360.77 points and the SBF 120 0.74%. The stock is among the highest risers in the broad index, trailing behind Soitec and LISI. However, the rebound is modest compared to the accumulated decline: the stock is down 10.58% over the week and 7.89% over the month, despite a nearly 45% increase over the year. The market context weighs on the entire stock exchange, with a more restrictive turn from major central banks noted yesterday in a Barclays report, while tensions around the Strait of Hormuz continue to maintain a risk premium on European assets.
Technical Setup Still Deteriorated After Annual Account Penalties
The stock continues to trade below its three moving averages, at 8.88% below the MM20 (€26.91), 5.66% below the MM50 (€25.99), and 5.51% below the MM200 (€25.95). The RSI at 38 indicates seller exhaustion following a 13.5% plunge after the annual financial report was published on June 17, which showed a net loss increased to €31.3 million despite a 42% increase in Uzedy royalties. Today's rebound brings the price back to the support level at €24.08, already tested earlier in the session. Opportunities identified during this June 16 publication notably include the commercial launch of Olanzapine LAI planned for Q4 2026, while the company warns of an expected increase in operating expenses. The resistance at €28.72, already crossed and then lost at the end of May, remains the next graphical level above the current price.
